Treating Women's Health through the Human Microbiome

With most of the research attention on the gut microbiome, there is a growing interest in the microbiome to better understand female reproductive, vaginal, and offspring health. More specifically, recent evidence has demonstrated that the vaginal microbiome plays an important role in successful fertilisation and health pregnancies. This workshop will review the current understanding of microbes in female health, as well as the opportunity to develop new microbiome-targeted products for diseases including HPV infections, bacterial vaginosis as well as pregnancy health.

Join this session to:
• Better identify how techniques are applied to determine a “healthy” vaginal microbiome
• Understand how the composition of the microbiome change for pregnant and postpartum women?
• Identify which health conditions can be better understood through analysis of the vaginal, oral and gut microbiome of women?
• Develop new microbiome-targeting products that help tackle widespread needs in women’s health

Using Metagenomics and the Human Microbiome to Address Antimicrobial Resistance

As the spread of infectious diseases and growing AMR continues within the hospital environment, information gathered from the microbiome, metagenomics, and bioinformatic analysis has been identified as a tool to help diagnose infections and stop the spread of infectious disease. This workshop will outline the tools required to create efficient microbiome systems that can help identify AMR pathogens, manage hospital systems, and protect humans against infectious disease.



Join this session to:

• Harness microbial information to understand how microbes evolve and spread in various environments, including hospitals
• Understand how new bioinformatics tools can be used to provide new insights on AMR pathogens
• Learn how artificial intelligence can better predict patterns to guide patient treatments
• Leverage insights gathered from the microbiome to fight infectious disease through the development of precision diagnostics


Learning from FMT to Inform Clinical
Trial Development of Microbiomebased Therapeutics

Often seen as the origin of microbiome-targeting therapies, FMT can provide important insights to drug developers and healthcare practitioners on the clinical
efficacy of bacteria-based therapeutics to help treat disease. This workshop will gather insights from clinical experts to discuss the important milestones of FMT as a therapeutic modality and understand how these insights can be leveraged to design more targeted microbiomebased therapeutics.




Join this session to:
• Gain an update on the current use of FMT as a modality to treat disease
• Understand the successes and challenges of using FMT in practice
• Learn how results from FMT interventions can help the drug development community learn the key clinical trial considerations for future microbiome-targeting therapies
• Develop standards in clinical microbiome intervention studies to better assess comparability of results

Dora Nagy-Szakal
James McIlroy

Ina Schuppe-Koistinen
Alliance Director, CTMR
Karolinska Institutet

Ina Schuppe Koistinen, PhD, Associate Professor, holds the position as Alliance Director at the Centre for Translational Microbiome Research (CTMR). The centre started in January 2016 as a collaboration between Karolinska Institutet, Science for Life Laboratory (SciLifeLab) and Ferring Pharmaceuticals in Stockholm, Sweden. Ina has pursued a career both in pharma industry and academia via a large number of academic collaborations and public-private partnerships in translational medicine research with long experience in biomarker discovery based on omics technologies, systems-based data integration and biomarker qualification. Her current research interest is in understanding the role of the microbiome to health with a focus on female reproduction.


Dora Nagy-Szakal
Biotia, Inc.

Dorottya earned her MD and PhD in clinical medicine from Semmelweis University of Medicine in Hungary. Holding postdoctoral fellowships at Baylor College of Medicine/Texas Children's Hospital and Columbia University, she has 10+ years of experience in translational medicine, pediatrics, gastroenterology, microbiology and clinical metagenomics. She led cutting-edge clinical trials on fecal microbiome transplantation and developed a multicenter research program to understand the role of the gut-brain axis in the integrative neuroscience field. Currently, Dorottya is the Chief Medical Officer at Biotia, a NYC-based startup focusing on rapid infectious disease diagnostics, surveillance, and prevention of hospital acquired infections powered by artificial intelligence.

James McIlroy
Founder and President